Now Reading
Key Dividend Stocks for March: Gilead, Novartis, Pfizer

Key Dividend Stocks for March: Gilead, Novartis, Pfizer

Dividend Stocks March

As we venture into March, market experts have identified key dividend stocks that merit consideration for investment: Gilead Sciences, Novartis, and Pfizer. Their recommendations come from a thorough analysis of the companies’ robust financial health, promising business plans, and recent profit outcomes.

Gilead Sciences, a leading player in biopharmaceutical research, has a promising future, stemming from significant contribution to medical advancements. Despite dealing with disappointments like the trial results of Trodelvy, a lung-cancer medication, they remain steadfast in their research expansion efforts and the potential of Trodelvy. The company’s shares rest near their 52-week low, which could spell an opportunity for future profits.

Meanwhile, global healthcare company, Novartis, downplays recent lackluster performance with a consistent specialty in increasing dividends – a record held for 27 years. No doubt, the company has exhibited strategic maneuvering, such as spinning off its generic and biosimilar drug division while widening its portfolio. Even in its state of restructure, the company saw an 8% increase in sales coupled with an 18% growth in EPS in 2023.

Pfizer stands tall with an impressive dividend yield of 6.2% and a consistent pattern of enhancing its dividends since 2010, come what may. Though their stock value took a considerable hit due to reduced vaccine demands, Pfizer’s diverse portfolio and innovative research offer a potential for future growth, making it an appealing choice for long-term investors.

See Also
Remove Unhelpful Content

Regardless of the promising insights, potential investors are advised to conduct thorough research and risk assessments, or even hire professional financial advisors for comprehensive market insights and investment strategies.

View Comments (0)

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll To Top